Provided by Tiger Fintech (Singapore) Pte. Ltd.

Fate Therapeutics

1.60
+0.260019.40%
Post-market: 1.58-0.0180-1.13%19:58 EDT
Volume:4.68M
Turnover:7.27M
Market Cap:183.41M
PE:-1.07
High:1.68
Open:1.36
Low:1.36
Close:1.34
Loading ...

Fate Therapeutics Q4 2024 GAAP EPS $(0.44) Misses $(0.43) Estimate, Sales $1.860 Miss $1.416M Estimate

Benzinga
·
06 Mar

Fate Therapeutics Q4 Operating Expenses USD 63.608 Million

THOMSON REUTERS
·
06 Mar

Fate Therapeutics Inc: Projected Operating Runway Through Ye26

THOMSON REUTERS
·
06 Mar

Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

GlobeNewswire
·
06 Mar

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
05 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
03 Mar

Will Fate Therapeutics (FATE) Report Negative Q4 Earnings? What You Should Know

Zacks
·
17 Feb

Fate Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire
·
15 Feb

IDEAYA Biosciences, Inc. (IDYA) Reports Q4 Loss

Zacks
·
13 Feb

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
05 Feb

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
05 Feb

We're Keeping An Eye On Fate Therapeutics' (NASDAQ:FATE) Cash Burn Rate

Simply Wall St.
·
04 Feb

Fate Therapeutics Announces Executive Leadership Transition

TIPRANKS
·
07 Jan

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
04 Jan

Fate Therapeutics (FATE) Up 0.5% Since Last Earnings Report: Can It Continue?

Zacks
·
13 Dec 2024

Barclays Gives a Buy Rating to Fate Therapeutics (FATE)

TIPRANKS
·
11 Dec 2024

Hold Rating for Fate Therapeutics Amid Incremental Progress in CD19 CAR-T Therapy Development

TIPRANKS
·
10 Dec 2024

Fate Therapeutics Reports FT819 Shows 'Favorable Safety Profile,' Clinical Benefits

MT Newswires Live
·
10 Dec 2024

BRIEF-Fate Therapeutics Presents New Phase 1 Clinical Data Of Ft819 Off-The-Shelf

Reuters
·
10 Dec 2024

Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 off-the-Shelf, Car T-Cell Product Candidate for Systemic Lupus Erythematosus

THOMSON REUTERS
·
10 Dec 2024